Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy.

Jiang W, Luo Z, Martin L, Wan Z, Fu P, Wagner A, Ling B, Heath SL, Haque A, McRae-Clark A.

Curr HIV Res. 2018;16(2):143-150. doi: 10.2174/1570162X16666180703151208.

2.

Impact of cannabis legalization on treatment and research priorities for cannabis use disorder.

Sahlem GL, Tomko RL, Sherman BJ, Gray KM, McRae-Clark AL.

Int Rev Psychiatry. 2018 Jun;30(3):216-225. doi: 10.1080/09540261.2018.1465398. Epub 2018 Jun 29.

PMID:
29956576
3.

Parenting outcomes of parenting interventions in integrated substance-use treatment programs: A systematic review.

Moreland AD, McRae-Clark A.

J Subst Abuse Treat. 2018 Jun;89:52-59. doi: 10.1016/j.jsat.2018.03.005. Epub 2018 Apr 3.

PMID:
29706173
4.

Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials.

Baker NL, Gray KM, Sherman BJ, Morella K, Sahlem GL, Wagner AM, McRae-Clark AL.

Drug Alcohol Depend. 2018 Jun 1;187:270-277. doi: 10.1016/j.drugalcdep.2018.03.017. Epub 2018 Apr 16.

PMID:
29698894
5.

Cannabis Withdrawal in Adults With Attention-Deficit/Hyperactivity Disorder.

Chauchard E, Hartwell KJ, McRae-Clark AL, Sherman BJ, Gorelick DA.

Prim Care Companion CNS Disord. 2018 Feb 22;20(1). pii: 17m02203. doi: 10.4088/PCC.17m02203.

6.

Approach bias modification for cannabis use disorder: A proof-of-principle study.

Sherman BJ, Baker NL, Squeglia LM, McRae-Clark AL.

J Subst Abuse Treat. 2018 Apr;87:16-22. doi: 10.1016/j.jsat.2018.01.012. Epub 2018 Jan 16.

PMID:
29471922
7.

Therapeutic Benefit of Smoked Cannabis in Randomized Placebo-Controlled Studies.

Bowen LL, McRae-Clark AL.

Pharmacotherapy. 2018 Jan;38(1):80-85. doi: 10.1002/phar.2064. Epub 2017 Dec 18. Review.

8.

Impact of endogenous progesterone on reactivity to yohimbine and cocaine cues in cocaine-dependent women.

Moran-Santa Maria MM, Sherman BJ, Brady KT, Baker NL, Hyer JM, Ferland C, McRae-Clark AL.

Pharmacol Biochem Behav. 2018 Feb;165:63-69. doi: 10.1016/j.pbb.2017.11.001. Epub 2017 Nov 7.

9.

Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial.

Tomko RL, Baker NL, McClure EA, Sonne SC, McRae-Clark AL, Sherman BJ, Gray KM.

Drug Alcohol Depend. 2018 Jan 1;182:1-7. doi: 10.1016/j.drugalcdep.2017.09.035. Epub 2017 Nov 2.

10.

Repetitive transcranial magnetic stimulation (rTMS) administration to heavy cannabis users.

Sahlem GL, Baker NL, George MS, Malcolm RJ, McRae-Clark AL.

Am J Drug Alcohol Abuse. 2018;44(1):47-55. doi: 10.1080/00952990.2017.1355920. Epub 2017 Aug 14.

11.

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR.

Drug Alcohol Depend. 2017 Aug 1;177:249-257. doi: 10.1016/j.drugalcdep.2017.04.020. Epub 2017 Jun 10.

12.

Comparing adult cannabis treatment-seekers enrolled in a clinical trial with national samples of cannabis users in the United States.

McClure EA, King JS, Wahle A, Matthews AG, Sonne SC, Lofwall MR, McRae-Clark AL, Ghitza UE, Martinez M, Cloud K, Virk HS, Gray KM.

Drug Alcohol Depend. 2017 Jul 1;176:14-20. doi: 10.1016/j.drugalcdep.2017.02.024. Epub 2017 May 10.

13.

The Gap in Leadership Training for Scientists from Underrepresented Groups.

Valles R, McRae-Clark A.

Behav Ther (N Y N Y). 2017 Mar;40(3):80-81. No abstract available.

14.

Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention.

Sherman BJ, Baker NL, McRae-Clark AL.

Psychiatry Res. 2017 Mar;249:318-320. doi: 10.1016/j.psychres.2017.01.027. Epub 2017 Jan 20.

15.

Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study.

Sherman BJ, McRae-Clark AL, Baker NL, Sonne SC, Killeen TK, Cloud K, Gray KM.

Am J Addict. 2017 Mar;26(2):136-144. doi: 10.1111/ajad.12503. Epub 2017 Feb 2.

16.

Impact of gender on corticotropin-releasing factor and noradrenergic sensitivity in cocaine use disorder.

McRae-Clark AL, Cason AM, Kohtz AS, Moran Santa-Maria M, Aston-Jones G, Brady KT.

J Neurosci Res. 2017 Jan 2;95(1-2):320-327. doi: 10.1002/jnr.23860. Review.

17.

Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women.

Sherman BJ, Baker NL, McRae-Clark AL.

Addict Behav. 2016 Sep;60:197-202. doi: 10.1016/j.addbeh.2016.04.014. Epub 2016 Apr 22.

18.

Treatment of Cannabis Use Disorder: Current Science and Future Outlook.

Sherman BJ, McRae-Clark AL.

Pharmacotherapy. 2016 May;36(5):511-35. doi: 10.1002/phar.1747. Review.

19.

Effects of yohimbine and drug cues on impulsivity and attention in cocaine-dependent men and women and sex-matched controls.

Moran-Santa Maria MM, Baker NL, McRae-Clark AL, Prisciandaro JJ, Brady KT.

Drug Alcohol Depend. 2016 May 1;162:56-63. doi: 10.1016/j.drugalcdep.2016.02.021. Epub 2016 Feb 23.

20.

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL.

Neuropsychopharmacology. 2016 Jul;41(8):1974-82. doi: 10.1038/npp.2015.367. Epub 2015 Dec 28.

Supplemental Content

Loading ...
Support Center